pharma news

News

Madrigal eyes combination MASH therapy with Pfizer deal

Madrigal Pharma is reheating a drug for metabolic dysfunction-associated steatohepatitis (MASH) put on ice by Pfizer last year.

News

Perlmutter's Eikon follows the IPO trail

Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.

News

J&J jumps on the MFN pricing train

Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.

News

FDA turns down Hetlioz for jet lag once again

Vanda will continue to push for approval of Hetlioz for jet lag, despite the FDA saying its trial designs were not satisfactory.

News

Now Iktos teams up with Pierre Fabre in oncology

As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos

News

$100 bill with missing puzzle pieces to be inserted

Parabilis scores $305m in bumper biofinancing week

Money has flooded into biotechs this week, with Parabilis raising $305m and five other start-ups closing nine-figure private rounds.

Madrigal eyes combination MASH therapy with Pfizer deal

Perlmutter's Eikon follows the IPO trail

J&J jumps on the MFN pricing train

FDA turns down Hetlioz for jet lag once again

Now Iktos teams up with Pierre Fabre in oncology

Parabilis scores $305m in bumper biofinancing week

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks